Glenmark Pharmaceuticals has introduced Travoprost Ophthalmic Solution USP, 0.004 percent (Ionic Buffered Solution).

Glenmark’s Travoprost Ophthalmic Solution USP, 0.004 percent is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004 percent of Sandoz, Inc.

According to IQVIATM sales data for the 12-month period ending September 2024, the Travatan Z Ophthalmic Solution USP, 0.004 percent market achieved annual sales of approximately USD 66.2 million.

Commenting on the launch, Jim Brown, Senior Vice President, Sales & Marketing said, “We are excited to announce the launch of Travoprost Ophthalmic Solution USP, 0.004 percent, growing our portfolio of prescription ophthalmic products. This addition highlights our commitment to meeting market needs and providing high-quality solutions for our customers.”

Glenmark’s current portfolio consists of 200 products authorized for distribution in the US marketplace and 51 ANDA’s pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.